Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

NCT00031564 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer

Interventions

BIOLOGICAL: Interleukin-2
BIOLOGICAL: B7-1

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]